Ferralet ® Absorption

Ferralet Mode of Action

Taking iron can be an unpleasant experience that includes coping with lots of side effects relating to your digestive system—anything from stomach cramps, to nausea, to constipation. These events commonly limit the amount of iron that can be given at one time,1 consequently prolonging the duration of treatment. Ferralet 90 contains a patented dual-iron formulation with ferrous gluconate for immediate uptake and carbonyl iron for more gradual absorption as it requires gastric acid to convert it to soluble iron.2 We call the process biocomplementary because iron is available for a prolonged period of time as the body needs to absorb more iron. Because of this slow, gradual process, side effects are low,3 and accidental poisoning in children is far less of a risk than it is with traditional irons.

Despite the slower, more gradual way carbonyl enters the system, it is equivalent to traditional iron in the volume absorbed and its circulation through the body.4

The patient's system defines the rate of absorption1

Ferralet Method of Action

  1. (a) Ferrous gluconate enters the body ready for immediate absorption (b)Particulate carbonyl iron is converted to soluble ionized iron at a rate determined by the rate of gastric acid production4

  2. Overall bioavailability is similar for carbonyl iron and ferrous salts4

  3. Ferralet 90 provides both the initial dose of ferrous iron and the more prolonged absorption of carbonyl iron

1 Gordeuk VR, Brittenham GM, Hughes M, Keating LJ, Opplt JJ. High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial. Am J Clin Nutr. 1987;46(6):1029-1034.

2 Barton JC. Iron deficiency. In: Rakel RE, Bope ET, eds. Conn’s Current Therapy. Amsterdam, the Netherlands: Saunders/Elsevier; 2008:385-389.

3 Brittenham GM, Klein HG, Kushner JP, Ajioka RS. Preserving the national blood supply. Hematol Am Soc Hematol Educ Program. 2001:422-432.

4 Huebers HA, Josephson B, Huebers E, Csiba E, Finch CA. Occupancy of the iron binding sites of human transferrin. Proc Natl Acad Sci USA. 1984;81(14):4326-4330.